Editorial
I n response to criticism from the American Medical Association (AMA), Congress, and other groups, the Pharmaceutical Research Manufacturers of America (PhRMA) published direct-toconsumer (DTC) advertising guidelines in August 2005. However, these guidelines do not contain any required waiting period from the time a new drug is approved and the time that consumer advertising may commence. Instead, the guidelines encourage pharmaceutical companies to spend an "appropriate" period informing health care professionals about new drugs before beginning DTC advertising. PhRMA guidelines also support advertising by pharmaceutical companies that better targets their audience and that includes a more thorough discussion of drug risks within DTC advertising. The guide lines are voluntary.
In June 2006, the AMA House of Delegates endorsed a policy requesting a temporary moratorium on DTC advertising of new prescription drugs and implantable medical devices. In a prepared statement, AMA president-elect Ronald Davis stated that "physicians will have the opportunity to become better educated on the pros and cons of prescription drug uses before prescribing them and will be better able to determine when they are best suited for their patients' medical needs." The AMA plans to request that the US Food and Drug Administration (FDA) enact the policy; hence, the length of the moratorium would be determined by the FDA.
The AMA also desires that the FDA approve all DTC advertisements prior to their publication, that the advertisements provide enough detail so that consumers understand the risks associated with the drugs advertised, that the advertisements are targeted to ageappropriate audiences, and that the advertisements refer patients to their physicians for full explanation of a drug's indications, effects, and other pertinent information.
The AMA had considered a ban on DTC advertising altogether; however, they chose to recommend only FDA oversight. The group felt there were some benefits to DTC advertising, including fostering a physician-patient dialogue about drugs and informing pa tients about the availability of new agents.
In 2006 the US Government Accountability Office (GAO) investigated how the FDA regulates DTC advertising and the effectiveness of administrative controls on advertising. 1 Studies reviewed by the GAO indicated that DTC advertising may increase drug spending by prompting patient requests for the advertised drugs from their physicians, who are generally responsive.
The FDA reviews a small portion of the DTC materials it receives. Previously, the agency had informal criteria for evaluating DTC submissions to aid in giving priority to those advertisements that may have the greatest impact on health. However, the FDA did not document these criteria nor did the agency routinely apply them and track the results of their use. Following a requirement for legal review of regulatory letters in 2002, the FDA has taken longer to draft and review these letters. From 2002 through 2005, it took the FDA an average of 4 months to issue a regulatory letter. This compares with an average of 2 weeks from 1997 through 2001. In 2004 and 2005, the FDA issued 19 regulatory letters that concerned 31 advertisements and that were issued an average of 8 months after the violative materials were first disseminated. By the time the letters were released, manufacturers of those drugs had already discontinued the use of more than half of the materials in question. Despite the delays in the FDA's review of submissions and release of regulatory letters, the GAO recommendations to the agency seem minimal: standardize criteria to identify advertisements of highest priority, implement the criteria, and track all reviewed advertisements. 2 It is unfortunate that the AMA did not more aggressively pursue a complete ban on all DTC advertising and that the GAO recommendations to the FDA were not more stringent. There is a level of naïveté in thinking that a consumer is able to understand the risks and/or benefits of a new agent and compare these with other agents that may be used for treating a condition. DTC advertising has led to, and will continue to lead to, overprescribing. Furthermore, much of *Editor-in-Chief, Hospital Pharmacy. Editorial this type of advertising is disease related in an attempt to convince consumers that they should be taking a drug when pharmacotherapy is not required. The belief that DTC advertising can be effectively regulated is also impractical because regulatory action is only taken af ter campaigns have been launched. The only way customers can be protected from deleterious drug advertising is by banning such advertising methods entirely.
